Talk:New Article Requests
Before You Submit a Proposal
- EVALUATION CRITERIA: Review these to be sure your proposal is eligible. The current acceptance rate for new articles is approximately 41%.
- EXISTING ARTICLES: Review these to see if your proposed topic is already included or could be included in an existing EyeWiki article. You can do this by performing a thorough search using various related key terms.
- If you find a pre-existing stand-alone article that addresses your topic or an article that includes your topic please edit the article to include your own input. You will be automatically recognized as a contributor to that article.
- Of those proposals that are not accepted, 85% are rejected because the topic is already covered or could be covered in an existing EyeWiki article.
- PROPOSALS PREVIOUSLY SUBMITTED: Review these and please do not resubmit these topics.
- PREAPPROVED TOPICS and ARTICLES NEEDING REVISION: Can't think of a topic for a new article? Consider revising topics on this list of articles flagged by the editorial board for revisions. Visit the discussion pages of these articles to find out what is needed. No approval is necessary to revise these articles. Currently, there are some new suggested topics that have been preapproved for stand-alone articles. Contact eyewiki@aao.org if you would like to work on one of the pre-approved new articles and can complete it within 30 days.
Instructions
- IMPORTANT: Review the section above "Before You Submit a Proposal"
- Click the "Add topic" link to create a new proposal on this page not in your own talk page.
- Then add the relevant list items as shown
- Title: Enter this in the Subject field
- Summary: Please provide some details about what will be covered and why you think the article would benefit EyeWiki. Do not submit a complete article.
- Section: Indicate what subspecialty section the article should be added to. You may indicate up to 2 sections.
- Submitted by: Name of the ophthalmologist submitting the proposal. Sign and date your request by entering 4 tilde ~ characters only. This will automatically add your username, a time stamp and a link to your profile. You will see this after you save the page.
- SAMPLE: Rayna.Ungersma.AAO (talk) 10:01, April 30, 2024 (PDT)
- Click: SAVE at the bottom of the page
Sample Proposal
Biosimilars in Ophthalmology
Summary: Patents for original biologics used to treat nAMD and DME are approaching expiration. Numerous companies are striving to replicate these biologics as biosimilars, which are drugs that mimic the effects of the original biologic, but do not have the same active ingredients. This article will summarize the current literature about biosimilars and their safety, efficacy, and quality and provide an in-depth review of approved biosimilars as well as those that are in development. This article will provide EyeWiki readers with information about numerous alternatives for treatment nAMD and DME.
Section: Retina/Vitreous
Submitted by: Rayna.Ungersma.AAO (talk) 15:04, May 1, 2024 (PDT)
Ocular Manifestations Sildenafil Toxicity
Summary: Sildenafil toxicity has been associated with a spectrum of ocular manifestations, reflecting the drug’s pharmacologic inhibition of phosphodiesterase type 5 (PDE5) and its partial cross-inhibition of phosphodiesterase type 6 (PDE6) in retinal photoreceptors. Transient visual disturbances are the most commonly reported effects and include bluish discoloration of vision (cyanopsia), increased light sensitivity, blurred vision, and altered color discrimination, particularly between blue and green hues. These symptoms are usually dose-dependent and reversible. More severe and less frequent ocular complications have been described, especially with high doses or misuse, including nonarteritic anterior ischemic optic neuropathy (NAION), central serous chorioretinopathy–like changes, retinal vascular events, and optic disc edema. Electrophysiologic studies have demonstrated transient changes in electroretinogram responses, supporting direct retinal involvement. Although a definitive causal relationship with permanent vision loss remains controversial, these potentially sight-threatening associations underscore the importance of cautious sildenafil use, particularly in patients with pre-existing optic nerve or vascular risk factors.
Section: Cataract/Anterior Segment
Submitted by: Hashem.AbuSerhan (talk) 07:23, February 6, 2026 (PST)

